The Proteomics Market size in the European region is expected to grow at a CAGR of 11.2% and reach USD 6.39 billion in 2025 from USD 3.76 billion in 2020.
Some of the factors driving the European market are growing criteria for personalized medicine, R&D use, and technological advances and increased funding for proteomics projects. Also, the different applications ranging from protein identification to purification and protein separation to nature and property study are the other factors promoting the growth of the Proteomics market.
Nevertheless, declining funds in critical markets, U.S. sequestration cuts, and reduced resources for proteomics research, great tool and equipment prices, and lack of talented scientists are some of the significant factors that limit the European market.
Positive government support and private research organizations ' initiatives for proteomics research, development of new technologies such as mass spectrometry, chemo proteomics, and increasing focus on new drug discoveries by biopharmaceutical companies are further assisting the growth of the global proteomics market.
This report on European Proteomics Market has been segmented and sub-segmented into the following categories:
Based on the application, the Clinical Diagnostics segment accounted for the largest share in 2019, owing to the increased understanding of structures of protein expression for drug development and diseases. The drug discovery segment is expected to grow at the highest CAGR due to a continuous search for efficient ways to deliver enhanced drugs.
Regionally, Europe continued to hold the second-largest share of the global proteomics market attributed to the region's substantial government funding. Besides, due to the increasing prevalence of chronic diseases in the area, the region has been an early accepter of new diagnostics and medications. It is predicted that microarrays are the key contributors, accounting for approx. 70% of the biochip market, while services contribute only 15%. Presently, only microarrays in protein-based diagnostics provide high-throughput screening. The United Kingdom is the major shareholder, 60% of the business, led by Germany and France.
Other regions competing with Europe are North America and the Asia Pacific. During the forecast period, the Asia Pacific market is likely to grow at the highest CAGR.
Noteworthy in the European proteomics Market
Companies like Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Bruker Corporation, Danaher Corporation, GE Healthcare, Luminex Corporation, Merck KGaA, PerkinElmer Inc., Thermo Fisher Scientific, Inc., and Waters Corporation are playing a crucial role in the European proteomics market.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Instrument
5.2 Reagent
5.3 Service & Software
5.4 Application
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
8.Market Leaders' Analysis
8.1 Agilent Technologies Inc.
8.2 Bio-Rad Laboratories, Inc.
8.3 Bruker Corporation
8.4 Danaher Corporation
8.5 GE Healthcare
8.6 Luminex Corporation
8.7 Merck KGaA
8.8 PerkinElmer Inc.
8.9 Thermo Fisher Scientific, Inc.
8.10 Waters Corporation
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
